Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 410

1.

Brentuximab vedotin for lymphoma in paediatric patients.

Sureda A, Domingo-Domènech E.

Lancet Haematol. 2018 Oct;5(10):e433-e434. doi: 10.1016/S2352-3026(18)30160-1. No abstract available.

PMID:
30290898
2.

Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).

Pavone V, Mele A, Carlino D, Specchia G, Gaudio F, Perrone T, Mazza P, Palazzo G, Guarini A, Loseto G, Eleonora P, Cascavilla N, Scalzulli P, Melpignano A, Quintana G, Di Renzo N, Tarantini G, Capalbo S.

Ann Hematol. 2018 Oct;97(10):1817-1824. doi: 10.1007/s00277-018-3379-5. Epub 2018 Jul 27.

PMID:
30054707
3.

[Peripheral neuropathy as a side effect of chemotherapy and targeted therapy].

Gießen-Jung C, von Baumgarten L.

Dtsch Med Wochenschr. 2018 Jul;113(13):970-978. doi: 10.1055/s-0043-120839. Epub 2018 Jul 4. Review. German.

PMID:
29972842
5.

Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma.

Qin Q, Nan X, Miller T, Fisher R, Teh B, Pandita S, Farach AM, Pingali SR, Pandita RK, Butler EB, Pandita TK, Iyer SP.

Radiat Res. 2018 Sep;190(3):322-329. doi: 10.1667/RR15048.1. Epub 2018 Jun 27.

PMID:
29949442
6.

Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis.

Tsirigotis P, Vassilakopoulos T, Batsis I, Bousiou Z, Gkirkas K, Sakellari I, Kaloyannidis P, Roussou P, Pangalis GA, Moschogiannis M, Vassilopoulos G, Repousis P, Megalakaki A, Michalis E, Kalpadakis C, Papadaki HA, Kotsianidis I, Hatzimichael E, Spyridonidis A, Anargyrou K, Poulakidas E, Giannoullia P, Apostolidis I, Stamouli M, Konstantopoulos K, Pappa V, Panayiotidis P, Harhalakis N, Anagnostopoulos A, Angelopoulou M.

Hematol Oncol. 2018 Oct;36(4):645-650. doi: 10.1002/hon.2521. Epub 2018 Jun 8.

PMID:
29882363
7.

Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors.

Carella AM, Corradini P, Mussetti A, Ricardi U, Vitolo U, Viviani S.

Ann Hematol. 2018 Aug;97(8):1301-1315. doi: 10.1007/s00277-018-3366-x. Epub 2018 May 25. Review.

PMID:
29802458
8.

Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma.

Canellos GP, LaCasce AS.

N Engl J Med. 2018 Apr 19;378(16):1560. doi: 10.1056/NEJMc1802363. No abstract available.

PMID:
29671468
9.

Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma.

Crump M.

N Engl J Med. 2018 Apr 19;378(16):1559-60. doi: 10.1056/NEJMc1802363. No abstract available.

PMID:
29671466
10.

Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma.

Greer JP.

N Engl J Med. 2018 Apr 19;378(16):1559. doi: 10.1056/NEJMc1802363. No abstract available.

PMID:
29671465
11.

Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma.

Hilal T.

N Engl J Med. 2018 Apr 19;378(16):1558-9. doi: 10.1056/NEJMc1802363. No abstract available.

PMID:
29671464
12.

Brentuximab Vedotin for Stage III or IV Hodgkin's Lymphoma.

Connors JM, Radford JA.

N Engl J Med. 2018 Apr 19;378(16):1560-1561. doi: 10.1056/NEJMc1802363. No abstract available.

13.

Utility of a high coverage phenyl-bonding and wide-pore superficially porous particle for the analysis of monoclonal antibodies and related products.

Bobály B, Lauber M, Beck A, Guillarme D, Fekete S.

J Chromatogr A. 2018 May 11;1549:63-76. doi: 10.1016/j.chroma.2018.03.043. Epub 2018 Mar 21.

PMID:
29602545
14.

Rapid and simultaneous quantification of a mixture of biopharmaceuticals by a liquid chromatography/quadrupole time-of-flight mass spectrometric method in rat plasma following cassette-dosing.

Park MH, Byeon JJ, Shin SH, Kim N, Park Y, Ill Lee B, Choi J, Shin YG.

Rapid Commun Mass Spectrom. 2018 Jun 15;32(11):889-896. doi: 10.1002/rcm.8123.

PMID:
29578307
15.

Choledochoduodenal Fistula during Chemotherapy with Brentuximab Vedotin for Methotrexate-associated Lymphoproliferative Disorder.

Eso Y, Uza N, Shirakawa K, Sawada K, Katsuragi K, Matsuura M, Seno H.

Intern Med. 2018 Aug 1;57(15):2203-2207. doi: 10.2169/internalmedicine.0557-17. Epub 2018 Mar 9.

16.

Tumor-stage mycosis fungoides in palmoplantar localization with large-cell transformation and partial CD30 expression shows complete response to brentuximab vedotin.

Pham AK, Carter JB, Ratcliffe NR, Fuld AD, Lansigan F, Burnside NJ, Guill MA 3rd, Zug KA, Jarvis LA, LeBlanc RE.

J Cutan Pathol. 2018 Jun;45(6):458-462. doi: 10.1111/cup.13140. Epub 2018 Apr 6.

PMID:
29512830
17.

A single liquid chromatography-quadrupole time-of-flight mass spectrometric method for the quantification of total antibody, antibody-conjugated drug and free payload of antibody-drug conjugates.

Byeon JJ, Park MH, Shin SH, Lee BI, Park Y, Choi J, Kim N, Kang Y, Shin YG.

Biomed Chromatogr. 2018 Jul;32(7):e4229. doi: 10.1002/bmc.4229. Epub 2018 Mar 30.

PMID:
29505175
18.

Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.

Elshenawy MA, Shahzad Rauf M, Elhassan TAM, Maghfoor I, Akhtar S.

Ann Hematol. 2018 Jul;97(7):1229-1240. doi: 10.1007/s00277-018-3283-z. Epub 2018 Feb 26.

PMID:
29484455
19.

Characterization of an antibody-drug conjugate by hydrophilic interaction chromatography coupled to mass spectrometry.

D'Atri V, Fekete S, Stoll D, Lauber M, Beck A, Guillarme D.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Mar 30;1080:37-41. doi: 10.1016/j.jchromb.2018.02.026. Epub 2018 Feb 20.

PMID:
29477065
20.

Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30.

Hogan LE, Vasquez J, Hobbs KS, Hanhauser E, Aguilar-Rodriguez B, Hussien R, Thanh C, Gibson EA, Carvidi AB, Smith LCB, Khan S, Trapecar M, Sanjabi S, Somsouk M, Stoddart CA, Kuritzkes DR, Deeks SG, Henrich TJ.

PLoS Pathog. 2018 Feb 22;14(2):e1006856. doi: 10.1371/journal.ppat.1006856. eCollection 2018 Feb.

Supplemental Content

Loading ...
Support Center